Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic Concepts of Sodium-Glucose Cotransporter 2 Inhibitors-Based Therapies Against Hepatocarcinogenesis and Therapy Resistance in Hepatocellular Carcinoma.

Life (Basel, Switzerland)·2026
Same author

Heat stroke-induced structural and functional impairments of cognition-relevant brain areas in mice is associated with alpha-7 nicotinic acetylcholine receptors downregulation.

European journal of pharmacology·2026
Same author

MPP<sup>+</sup> disorders Irg1-Itaconate axis to promote M1 polarization of microglia by activating succinate dehydrogenase.

Molecular biology reports·2025
Same author

IPSC-Derived Conditioned Medium Reduces Oxidative Stress and Vascular Remodeling in Rat Models of Pulmonary Arterial Hypertension.

Journal of cellular physiology·2025
Same author

The dysregulation of high glucose-induced iPSC-neural stem cells differentiation by caspase-1.

Neuroscience letters·2025
Same author

The multifaceted modulations by dapagliflozin in preventing hyperglycemia-induced diabetic nephropathy through glucose transporters and PPARα.

Journal of diabetes and metabolic disorders·2025
Same journal

RETRACTION: Isolation of Antidiabetic Principle from Fruit Rinds of <i>Punica granatum</i>.

Evidence-based complementary and alternative medicine : eCAM·2026
Same journal

RETRACTION: Molecular Mechanism of Traditional Chinese Ointment of Xuzhou Qufu Shengji in Infected Wounds.

Evidence-based complementary and alternative medicine : eCAM·2026
Same journal

RETRACTION: Involvement of Endoplasmic Reticulum Stress in Capsaicin-Induced Apoptosis of Human Pancreatic Cancer Cells.

Evidence-based complementary and alternative medicine : eCAM·2026
Same journal

RETRACTION: Thujone-Rich Fraction of <i>Thuja occidentalis</i> Demonstrates Major Anti-Cancer Potentials: Evidences from In Vitro Studies on A375 Cells.

Evidence-based complementary and alternative medicine : eCAM·2026
Same journal

RETRACTION: Application of <i>Antrodia camphorata</i> Promotes Rat's Wound Healing <i>In Vivo</i> and Facilitates Fibroblast Cell Proliferation <i>In Vitro</i>.

Evidence-based complementary and alternative medicine : eCAM·2026
Same journal

RETRACTION: Catechins and Sialic Acid Attenuate <i>Helicobacter pylori</i>-Triggered Epithelial Caspase-1 Activity and Eradicate <i>Helicobacter pylori</i> Infection.

Evidence-based complementary and alternative medicine : eCAM·2026
See all related articles

Related Experiment Video

Updated: May 11, 2026

Extraction and Analysis of Taiwanese Green Propolis
06:50

Extraction and Analysis of Taiwanese Green Propolis

Published on: January 7, 2019

Decrease of Plasma Glucose by Hibiscus taiwanensis in Type-1-Like Diabetic Rats.

Lin-Yu Wang1, Hsien-Hui Chung, Juei-Tang Cheng

  • 1Department of Pediatrics, Chi-Mei Medical Center, Yong Kang, Tainan City 73101, Taiwan ; The Center of General Education, Chia Nan University of Pharmacy & Science, Rende, Tainan City 71710, Taiwan.

Evidence-Based Complementary and Alternative Medicine : Ecam
|May 22, 2013
PubMed
Summary
This summary is machine-generated.

Hibiscus taiwanensis effectively lowers blood glucose in diabetic rats by enhancing insulin sensitivity. This herbal extract reduces liver phosphoenolpyruvate carboxykinase (PEPCK) and increases skeletal glucose transporter 4 (GLUT 4).

Related Experiment Videos

Last Updated: May 11, 2026

Extraction and Analysis of Taiwanese Green Propolis
06:50

Extraction and Analysis of Taiwanese Green Propolis

Published on: January 7, 2019

Area of Science:

  • Pharmacology
  • Biochemistry
  • Herbal Medicine

Background:

  • Hibiscus taiwanensis is a traditional herb used in Taiwan for various ailments.
  • Diabetic hyperglycemia remains a significant health concern globally, necessitating novel therapeutic strategies.
  • Streptozotocin-induced diabetic rats (STZ-diabetic rats) are a common model for studying anti-diabetic agents.

Purpose of the Study:

  • To investigate the anti-diabetic effects of Hibiscus taiwanensis extract on hyperglycemia in STZ-diabetic rats.
  • To determine the specific plant part of Hibiscus taiwanensis most effective for glucose-lowering.
  • To elucidate the molecular mechanisms underlying the glucose-lowering action of Hibiscus taiwanensis.

Main Methods:

  • Oral administration of Hibiscus taiwanensis extract to STZ-diabetic rats.
  • Dose-response assessment of plasma glucose reduction.
  • Measurement of insulin sensitivity.
  • Analysis of hepatic phosphoenolpyruvate carboxykinase (PEPCK) expression.
  • Assessment of skeletal muscle glucose transporter subtype 4 (GLUT 4) expression.

Main Results:

  • Hibiscus taiwanensis extract demonstrated a significant plasma glucose-lowering effect in STZ-diabetic rats.
  • The stems of Hibiscus taiwanensis were found to be more potent in reducing plasma glucose in a dose-dependent manner.
  • Treatment increased insulin sensitivity and modulated key metabolic enzymes and transporters, including reduced hepatic PEPCK and increased skeletal GLUT 4.

Conclusions:

  • Hibiscus taiwanensis possesses significant anti-diabetic properties, effectively managing hyperglycemia in a rat model.
  • The herb enhances glucose utilization by upregulating skeletal muscle GLUT 4 and downregulating hepatic PEPCK.
  • These findings support the traditional use of Hibiscus taiwanensis and suggest its potential as a therapeutic agent for diabetes management.